pan-Canadian Pharmaceutical Alliance (pCPA): March 2019 Negotiation Status Update The pan-Canadian Pharmaceutical Alliance (pCPA) has issued the status of brand negotiations as of March 31, 2019. Highlights since the last update include: 5 negotiations completed for a total of 247 completed negotiations 2 negotiations closed, for a total of 35 closed negotiations No new files closed without negotiations, for a total of 63 … Read More →
pCPA Trends and Insights – Two Biosimilars Initiated Negotiations and Two Multi-Indication Negotiations were Completed
pan-Canadian Pharmaceutical Alliance (pCPA): February 2019 Negotiation Status Update The pan-Canadian Pharmaceutical Alliance Office (pCPAO) has issued the status of brand negotiations as of February 28, 2019. The key highlights since the last update are: 8 negotiations were completed for a total of 242 completed negotiations No negotiations were closed, for a total of 33 closed negotiations The pCPA decided to decline negotiations … Read More →
MORSE Consulting Releases its 2018 pCPA Year in Review Infographic
MORSE Consulting is pleased to release its 2018 pCPA Year in Review infographic. The purpose of this resource is to help market access professionals provide a top-line pCPA performance summary to both internal and external stakeholders. This infographic compares the negotiation activities of the pCPA in 2018 to 2017 as it relates to: completed negotiations by source (CDR, pCODR, pCPA initiated); a breakdown of … Read More →
Summary of PMPRB Webinar on Meds Entry Watch, 2017
MORSE Consulting has prepared a summary of the key highlights from the Patented Medicines Prices Review Board’s (PMPRB) recent webinar on the release of their Meds Entry Watch 2017 report (third edition). Date: February 20th 2019 Time: 1pm-2pm Presented by: Elena Lungu (Manager NPDUIS, PMPRB), Jared Berger (Policy Analyst, Policy and Economic Analysis Branch, PMPRB) Objective: To present the Meds Entry Watch, 2017 report … Read More →
A Healthcare-focused Analysis of British Columbia’s 2019 Budget
MORSE Consulting is pleased to release a new report by Stephen Filbey of WestPAR Consulting, one of its strategic partners, entitled A Pharma industry Perspective/Opinion on British Columbia’s 2019 Budget. The NDP Government of BC, under the first non-majority legislature since 1952, has just released its second budget. With a strong economy, balanced operating budget, and an estimated $340 million in surplus over the … Read More →
pCPA Negotiation Status Update January 2019 – Two Oncology Negotiations Closed without LOI
pan-Canadian Pharmaceutical Alliance (pCPA): January 2019 Negotiation Status Update The pan-Canadian Pharmaceutical Alliance Office (pCPAO) has issued the status of brand negotiations as of January 31, 2019. The key highlights since the last update are: 3 negotiations were completed for a total of 234 completed negotiations 3 negotiations were closed, for a total of 33 closed negotiations The pCPA decided to decline negotiations … Read More →
Spotlight on the Atlantic Provinces: pCPA Letter of Intent Conversion and Time-to-Listing Analysis
MORSE Consulting is pleased to release a new report entitled Spotlight on the Atlantic Provinces: pCPA Letter of Intent Conversion and Time-to-Listing Analysis. While the majority of Canadians have some form of prescription medication coverage, the speed and extent to which individual patients gain access to new therapies, can vary significantly. As new drugs (and expanded indications for existing drugs) are approved by Health … Read More →
pCPA Process Timelines Highlights – A Year-in-Review Primer
pan-Canadian Pharmaceutical Alliance (pCPA): December 2018 Negotiation Status Update The pan-Canadian Pharmaceutical Alliance Office (pCPAO) issued the status of brand negotiations as of December 31, 2018. The key highlights since the November update are: 5 products received a final HTA recommendation, for a total of 13 files under consideration 2 products initiated pCPA negotiations, for a total of 46 active negotiations 7 negotiations … Read More →
pCPA Complete its Most Active Month by Adjudicating 15 Files in November
pan-Canadian Pharmaceutical Alliance (pCPA): November 2018 Negotiation Status Update The pan-Canadian Pharmaceutical Alliance Office (pCPAO) has issued the status of brand negotiations as of November 30, 2018. The key highlights since the October update are: 7 new drug products have initiated pCPA negotiations, for a total of 51 active negotiations; 9 negotiations were completed for a total of 225 completed negotiations; and 2 … Read More →
International Experience with Pharmaceutical Managed Entry Agreements
Toronto, December 13, 2018 – Neil Grubert and MORSE Consulting are pleased to announce the release of a new report entitled Pharmaceutical Managed Entry Agreements – Lessons Learned from Europe, the United States, Canada, and Australia. A performance or outcomes-based agreement (OBA) tracks the effectiveness of a drug in a defined patient population over a specified period of time and directly links the price … Read More →
BC Pharmacare Now Transitioning Patients on Copaxone® to GLATECT™
On November 27, 2018 the BC Ministry of Health changed coverage of glatiramer products, GLATECT™ and COPAXONE®, which demonstrates a shift from previous public drug plan approaches for funding of subsequent entry products (biosimilars) for chronic diseases. Background GLATECT™ is the first subsequent entry glatiramer-based treatment available for reimbursement for RRMS in Canada – i.e. a follow on product to Copaxone®. It … Read More →
Number of Active pCPA Negotiations at an All-Time High and Continues to Climb
pan-Canadian Pharmaceutical Alliance (pCPA): October 2018 Negotiation Status Update The pan-Canadian Pharmaceutical Alliance Office (pCPAO) has issued the status of brand negotiations as of October 31, 2018. The key highlights since the September update are: 6 new drug products have initiated pCPA negotiations, for a total of 57 active negotiations; 2 negotiations were completed for a total of 216 completed negotiations; and 1 … Read More →
Significant Developments in Canadian Drugs for Rare Disease Policy
Summary of Expensive Drugs for Rare Diseases (EDRD) Working Group Webinar Signals Decoded: Stakeholder consultation is underway on a supplemental process for complex/specialized drugs that builds upon the existing national HTA and reimbursement process to make responsive funding decisions with a focus on non-oncology therapies. The supplemental process is a significant development in EDRD policy and it looks to streamline the evaluation … Read More →
Presidents’ Roundtable – CAHR Market Access 201: Flying Blind – Navigating Patient Access through Uncertainty
Panel 6: Presidents’ Roundtable Panel Description: This session brought together general managers from three innovative pharmaceutical companies operating in Canada to explore their insights on how the current reimbursement environment is impacting their company, its decision-making and patient access. Moderator: Barbara Jaszewski Panelists: Peter Brenders, Brian Canestraro and Ben Faienza Barbara Jaszewski: CAHR 201 has been a great way to get a fast … Read More →
Summary of the CADTH Drug Portfolio Information Session Nov. 2018
Summary of CADTH Drug Portfolio Information Session Date: Thursday, November 1, 2018 Time: 1:30 pm to 4:00 pm Presenters: Brian O’Rourke, Brent Fraser, Alex Chambers, Trevor Richter, Heather Logan, Tarry Ahuja, Michelle Mujoomdar, Harindra Wijeysundera Purpose: An opportunity for all interested stakeholders to get the latest information about priority initiatives and process changes from CADTH’s pharmaceutical reviews portfolio, including the CADTH Common Drug … Read More →
MORSE Consulting Inc. | Deciphering pharmaceutical market access signals to create reimbursement success.
© 2019 MORSE Consulting Inc. All rights reserved. |
Site by Directica Media
MORSE Market Access Signals - Latest in Pharmaceutical Reimbursement
